Ind-Swift Labs FY26: Net Debt-Free, But ROCE Still Playing Possum

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

A 2,695% profit spike, a debt-free sheet, a ₹1,650 Cr divestment, and a 43% promoter grab. The company shrank revenue 63% in FY26 (from ₹709 Cr to ₹641 Cr), yet posted ₹49.4 Cr profit versus a ₹250 Cr gain in FY25 laced with ₹305 Cr of non-operating income.

The reset was surgical: APIs and CRAMS sold. The balance sheet flipped from ₹217 Cr debt to ₹18 Cr borrowings. The multiple sits at 28.9x current earnings—above the peer median of 31.9x, the company’s 5-year average of 16.9x, and its own 10-year average.

Operating margins shrank from 18% to 7%. Return on equity ran at 3.87%; return on capital employed at 4.7%. Both belong in a business-school cautionary tale.

The tension: a phoenix balance sheet paired with a phoenix-stage business model—clean slate, zero proof.

2. Introduction

Ind-Swift Laboratories Ltd started as an API house in 1995. For decades it chased complex chemistry and regulatory approvals across USFDA, MHRA, PMDA, ANVISA, TGA. By FY24, the API and CRAMS arms were printing money: ₹539 Cr profit on ₹1,709 Cr revenue—a 31.6% net margin, warped upward by ₹476 Cr other income and ₹539 Cr net profit.

Then in March 2024, it sold the API and CRAMS business to Synthimed Labs (a Bain Capital portfolio company) for ₹1,650 Cr. The same month, it merged the original parent company, Ind-Swift Limited, into the listed entity.

FY25 was a transition year: nine months of old operations (APIs, revenue ₹562 Cr, profit ₹250 Cr, heavy non-operating gain ₹305 Cr), then new formulation-focused business. By FY26, it was pure play: formulations, exports, domestic finished goods.

The share price responded: ₹83.96 in FY25 to ₹131.43 in FY26 (57% annual gain). As of June 10, 2026, it trades at ₹165—a 24.6% premium to FY26 close.

3. Business Model: WTF Do They Even Do?

Post-divestment, Ind-Swift is a finished dosage formulation (FDF) company. Two engines:

International (GBU—Global Business Unit): Export-driven, TGA/MHRA/Health Canada approved. Three verticals: Contract Manufacturing (CMO) for partners like Viatris, Wockhardt, Chanelle; Own-Brand greenfield ops in UAE, Africa, CIS (166 brands in Africa+FWA, 146 in SEA, 88 in CIS, 48 in UAE); and Out-Licensing IP (1,915 dossiers filed, 520 approvals). Facilities: Derabassi (≈81k sqm, tablets 9 billion/yr, capsules 90M/yr, sachets 111M/yr); Samba (14.7k sqm, EOU status).

Domestic: Ethical generics (76% gross margin), generics (OTC), P2P (contract manufacturing for domestic players like Cipla, Lupin, Mankind). 260+ marketing reps, 25k doctors, 2,400 stockists. Two facilities. Cash-generative, boring, necessary.

The asset: 520+ global approvals, presence in 85 countries, sticky CMO relationships (9–10 year contracts), R&D centre in Panchkula with 60+ scientists.

The bet: scale FDF revenue from ₹550 Cr (FY25 effective) to ₹1,200+ Cr by FY29; triple CDMO from ₹180 Cr to ₹550–600 Cr; lift EBITDA margin by 250–300 bps via mix-shift to high-margin ethical and export brands.

The risk: it’s guesswork until executed. Pre-transformation it was APIs; now it claims formulations. No history, no P&L proof, no 10-year track record.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Quarterly Results (Q4 FY26 vs. Q3 FY26):

Revenue ticked up. Operating EBITDA expanded—a 6.6% gain driven by falling raw material and employee costs. PAT jumped 22.6%, though off a low base (₹9.54 Cr in Q3).

Annual Results (FY26 vs. FY25):

The base effect: FY25 lumped in ₹305 Cr of non-operating income (largely ₹1,650 Cr divestment proceeds, recorded as a one-off gain). FY26 saw ₹36 Cr other income—a 88% cliff. Strip the noise: operating profit recovered from negative to ₹44.96 Cr.

9M FY26 vs. 9M FY25:

Operating EBITDA surged 214.8% (₹8.29 Cr → ₹26.09 Cr); operating margin widened 362 bps (2.01% → 5.63%). The progression quarter-on-quarter shows settling operations.

Concall Themes (Feb 2026 Presentation):

Management flagged: Q3 FY26 revenue stable at ₹177 Cr (vs. Q2’s ₹168 Cr and Q1’s ₹163 Cr). Operating EBITDA margin hit 5.95% in Q4—the best of the year, driven by cost discipline. Full-year EBITDA including non-operating income: ₹46.36 Cr (FY25: ₹82.38 Cr, inflated by the divestment one-off).

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 28.9x earnings here versus a 5-year average of 16.9x. The peer cohort (Sun Pharma, Divi’s Labs, Torrent, Cipla, Lupin, Zydus, Dr Reddy’s) trades at a median of 31.9x.

The P/B ratio stands at 1.05x—the company is almost at book value—while peers sit at 3.66x. That signals the market does not expect a revaluation event.

The market appears to be pricing in: a reset to formulations (not APIs), the Viatris CDMO partnership ramp (₹200–220 Cr incremental